Trial Purpose

This sub-study is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Sub-study 04A will enrol participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.

Learn More on



When speaking to your doctor, please have the trial identifier number available.

About The Study

Trial Phase Icon

Phase 1

Tests the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital.

Phase 2

Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.

Trial start Icon


  • Actual study start date 16 November 2022
  • Estimated primary completion date 28 October 2027
  • Estimated study completion date 28 October 2027


Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon


Urothelial Carcinoma

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon



Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.